(Q37508601)

20 August 2017

1 reference

title

Hallucinations in Parkinson disease (English)

1 reference

20 August 2017

1 reference

1 reference

4

Christopher G Goetz

1 reference

20 August 2017

Nico J Diederich

1

1 reference

20 August 2017

Gilles Fénelon

series ordinal

2

1 reference

20 August 2017

Glenn Stebbins

series ordinal

3

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

20 August 2017

published in

Nature Reviews Neurology

1 reference

20 August 2017

volume

5

1 reference

20 August 2017

issue

6

1 reference

20 August 2017

page(s)

331-342

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2009.62

20 August 2017

exact match

0 references

cites work

Hallucinations in Parkinson disease in the prelevodopa era.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Levodopa-induced psychosis: a kindling phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Psychiatric symptoms and syndromes in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Effects of levodopa in Parkinsonian patients with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Acute postoperative confusion and hallucinations in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Psychiatric comorbidities in patients with Parkinson disease and psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Hallucinations and sleep disorders in PD: six-year prospective longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Prospective longitudinal assessment of hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Risk factors for nursing home placement in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Longitudinal outcome of Parkinson's disease patients with psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Visual hallucinations associated with Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Visual perception in Parkinson disease dementia and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

The role of input relevance in sensory isolation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Hallucinations and sleep-wake cycle in PD: a 24-hour continuous polysomnographic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Altered cortical visual processing in PD with hallucinations: an fMRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Increased mortality among elderly patients with dementia using atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Visual hallucinations in Parkinson's disease: clues to separate origins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Characteristics of visual hallucinations in Parkinson disease dementia and dementia with lewy bodies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

[Visual hallucinations in Parkinson and Charles Bonnet Syndrome patients. A phenomenological and pathogenetic comparison]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Visual hallucinations in Parkinson's disease: a review and phenomenological survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Prospective study of hallucinations and delusions in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Hallucinosis in idiopathic Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Auditory hallucinations in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Tactile hallucinations in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Relationship between age and subtypes of psychotic symptoms in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Scales to assess psychosis in Parkinson's disease: Critique and recommendations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Risk factors for somnolence, edema, and hallucinations in early Parkinson disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

The malignant course of "benign hallucinations" in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Clinical phenotype of Parkinson disease dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Evidence of a Monoaminergic-Cholinergic Imbalance Related to Visual Hallucinations in Lewy Body Dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Delusions associated with elevated muscarinic binding in dementia with Lewy bodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Cortical acetylcholine, reality distortion, schizophrenia, and Lewy Body Dementia: too much or too little cortical acetylcholine?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Dopamine action and disorders of neurotransmitter balance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Treatment with tryptophan of levodopa-associated psychiatric disturbances

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

L-tryptophan administration in L-dopa-induced hallucinations in elderly Parkinsonian patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Hallucinations in Parkinson's disease: a follow-up study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Selective diplopia in Parkinson's disease: a special subtype of visual hallucination?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Impaired visual acuity as a risk factor for visual hallucinations in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Progressive worsening of spatial and chromatic processing deficits in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Independent patterns of damage within magno-, parvo- and koniocellular pathways in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

A model of the Parkinsonian visual system: support for the dark adaptation hypothesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Visual loss as a causative factor in visual hallucinations associated with Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Reality monitoring and visual hallucinations in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Impaired recognition of facial expressions of anger in Parkinson's disease patients acutely withdrawn from dopamine replacement therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Facial expression recognition in people with medicated and unmedicated Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Impaired visual search in drivers with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Impaired navigation in drivers with Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Cognitive performance in REM sleep behaviour disorder: a possible early marker of neurodegenerative disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Visual hallucinations as REM sleep behavior disorders in patients with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Update on the pharmacology of REM sleep behavior disorder.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Staging of brain pathology related to sporadic Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Hypocretin (orexin) loss in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Effect of time-of-day on the yawning response to apomorphine in normal subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Dopaminergic control of sleep-wake states.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Biologic rhythms and Parkinson's disease: a chronopharmacologic approach to considering fluctuations in function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Circadian rest-activity rhythm is altered in Parkinson's disease patients with hallucinations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Neuropsychological deficits in Parkinson's disease patients with visual hallucinations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Visual object recognition and attention in Parkinson's disease patients with visual hallucinations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Fluctuations in attention: PD dementia vs DLB with parkinsonism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Factors associated with drug-induced visual hallucinations in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Cognitive changes in Parkinson's disease patients with visual hallucinations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

HLA typing does not predict REM sleep behaviour disorder and hallucinations in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Neurobiology of retinal dopamine in relation to degenerative states of the tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Retinal nerve fiber layer thinning in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Retinal involvement in dementia with Lewy bodies: a clue to hallucinations?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

ERG and anatomical abnormalities suggesting retinopathy in dementia with Lewy bodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Cerebral atrophy in Parkinson's disease patients with visual hallucinations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Brain response to complex visual stimuli in Parkinson's patients with hallucinations: a functional magnetic resonance imaging study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Visual hallucination in Parkinson's disease with FDG PET.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Visual hallucinations and the Charles Bonnet syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

The anatomy of conscious vision: an fMRI study of visual hallucinations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

The cognitive neuroscience of sleep: neuronal systems, consciousness and learning

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Coping strategies for visual hallucinations in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Clozapine in Parkinson's disease psychosis: 5-year follow-up review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Brain-derived neurotrophic factor gene polymorphisms in Japanese patients with sporadic Alzheimer's disease, Parkinson's disease, and multiple system atrophy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Quetiapine improves psychotic symptoms and cognition in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Psychosis associated with clonazepam therapy for blepharospasm

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

31 March 2020

12 December 2020

Interictal acute psychoses in temporal lobe epilepsy during withdrawal of anticonvulsant therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.62

Pharmacology of hallucinations induced by long-term drug therapy

31 March 2020

1 reference

12 December 2020

Psychiatric disturbances in Parkinson's disease.

1 reference

12 December 2020

The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson's disease.

1 reference

12 December 2020

Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system

1 reference

12 December 2020

Delusions associated with elevated muscarinic binding in dementia with Lewy bodies.

1 reference

12 December 2020

Cholinergic and dopaminergic activities in senile dementia of Lewy body type.

1 reference

12 December 2020

Risks and benefits of antipsychotic drugs in elderly patients with dementia.

1 reference

12 December 2020

New developments in the pathology of Parkinson's disease

1 reference

12 December 2020

Hallucinations in Parkinson's disease: the clinical syndrome.

1 reference

12 December 2020

1 reference

12 December 2020

Olanzapine treatment for dopaminergic-induced hallucinations

1 reference

12 December 2020

Depression as a cause of hallucinations in Parkinson's disease.

1 reference

12 December 2020

Poor visual discrimination and visual hallucinations in Parkinson's disease

1 reference

12 December 2020

Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences

1 reference

12 December 2020

Decreased dopamine in the retinas of patients with Parkinson's disease

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEUROL.2009.62

1 reference

20 August 2017

1 reference